<DOC>
	<DOCNO>NCT01093937</DOCNO>
	<brief_summary>Bipolar Disorder chronic relapse mental disorder characterize period elevate , expansive irritable mood , often alternate period significant clinical depression . People Bipolar Disorder typically heavy smoker difficulty quit , associate significant tobacco-related medical illness death . The propose study double-blind , placebo-controlled 10-week clinical trial safety efficacy varenicline ( Champix™ ) thirty subject Bipolar I Disorder . This medication late first-line pharmacotherapy smoking cessation show efficacious smoke cessation , yet systematically studied person Bipolar Disorder .</brief_summary>
	<brief_title>Study Varenicline ( Champix ) Smoking Cessation/Reduction Patients With Bipolar Disorder</brief_title>
	<detailed_description>Varenicline ( VAR ) α4β2 central nicotinic acetylcholine receptor ( nAChR ) partial agonist . It believe mimic effect nicotine stimulate nAChRs release sufficient dopamine order reduce crave withdrawal effect . In past two year since approval VAR increase concern medication , particularly psychiatric smoker . Besides typical side effect nausea insomnia , associate treatment-emergent suicidality , aggression , psychosis , induction hypomania mania . Study Design : Thirty nicotine-dependent cigarette smoker Bipolar I Disorder enrol ( N=30 ) . All subject symptomatically stable prior enrollment , compliant mood-stabilizer medication treatment minimize chance adverse outcome . The treatment group would receive flexible dos varenicline ( VAR ) range one four capsule ( 0.5-2.0 mg ) orally per day . The control group would receive one four capsule placebo VAR ( 0 mg ) orally per day . All subject would receive weekly Cognitive Behavioral Therapy ( CBT ) offer group format help deal tobacco craving mood management . The target quit date would set Week 3 trial . Comprehensive neuropsychological assessment laboratory test give baseline ten week ; Hypotheses : 1 . Varenicline superior placebo smoke cessation outcome . 2 . Varenicline well-tolerated safe use Bipolar I smokers comparison placebo . 3 . Varenicline reduce smoking index ( Carbon monoxide , cotinine ) minimal effect psychiatric symptomatology mood-stabilizer treat Bipolar I smoke patient . 4 . The presence prefrontal cortical , impulsivity attentional deficit baseline neuropsychological battery predict smoke cessation treatment failure Bipolar I smoker . Significance : - This would first placebo-controlled clinical trial use varenicline treatment tobacco dependence people Bipolar Disorder . - There immense need safe effective smoking cessation therapy smoker bipolar illness . The co-morbidity major psychiatric disorder nicotine dependence well establish . The prevalence cigarette smoking patient bipolar disorder approximately 50-70 % compare ~19 % Canadian population . Moreover , smoker Bipolar Disorder suffer high extent smoking-related illness non-psychiatric smoker .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Structured Clinical Interview ( SCID ) derive DSMIV diagnosis Bipolar Disorder ( Type I II ) , Nicotine Dependence Young Mania Rating Scale Total Score &lt; 12 study entry HAMD 17Item Score &gt; 5 &lt; 24 study entry Fagerstrom Test Nicotine Dependence ( FTND ) score 5 high Be able provide inform consent participate study judge clinical evaluation , score least 80 % postconsent `` test '' Smoking least 10 cigarette per day ( confirm expire breath CO level &gt; 10 ppm plasma cotinine level &gt; 150 ng/ml baseline ) Be motivate quit smoking within 30 day initial evaluation , assess score 7 high Contemplation Ladder assessment tool On stable dose mood stabilizer least 1 month ( e.g . lithium , valproate , carbamazepine , atypical antipsychotic ) Judged study psychiatrist and/or train psychiatric clinician remission active manic , hypomanic , major depressive psychotic symptom base clinical interview SCIDIV ≥1 month prior study enrollment Meet criterion current abuse dependence alcohol illicit substance within past 3 month study enrollment Current evidence SCIDIV clinical evaluation suicidality , homicidality psychosis Meet DSMIV criterion current major depression time baseline evaluation A history hypersensitivity know adverse reaction ( e.g . hyperstimulation , severe agitation ) varenicline . Serious medical condition ( i.e . history severe cardiac , renal hepatic disease , diabetes mellitus thyroid abnormality ) EKG abnormalities Prescription Nicotine Replacement Therapies ( NRTs ) include patch , gum , lozenges inhaler Prescription monoamine oxidase inhibitor ( MAOI 's ) include selegiline moclobemide Prescription varenicline Prescription bupropion SR The presence manic , mixed manic hypomanic symptom past one month prior study enrollment . A lifetime history antidepressantinduced mania hypomania A history suicidal ideation take antidepressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Bipolar disorder</keyword>
	<keyword>Bipolar-I</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Champix</keyword>
	<keyword>Chantix</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Nicotinic receptor</keyword>
	<keyword>Nicotinic receptor dysregulation</keyword>
	<keyword>Dopamine</keyword>
	<keyword>Acetylcholine</keyword>
	<keyword>Cigarette</keyword>
	<keyword>Smoking</keyword>
	<keyword>Tobacco</keyword>
	<keyword>Dependence</keyword>
	<keyword>Neuropsychological function</keyword>
</DOC>